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Impact of Smoking Status in
Patients With Non–ST-Segment
Elevation Myocardial Infarction
The Reverse Smoker’s Paradox*
Jorge A. Belardi, MD
Buenos Aires, Argentina
Cigarette smoking (CS) constitutes an independent major
risk factor for total atherosclerotic cardiovascular disease and
is the leading preventable cause of mortality (1). Despite the
solid evidence about the deleterious effect of CS on car-
diovascular disease, several large clinical trials have demon-
strated that smokers who have an ST-segment elevation
myocardial infarction (STEMI) share better short-term
survival than nonsmokers (2). This survival advantage was
termed the smoker’s paradox more than 3 decades ago,
and appears to be partly related to a lower baseline risk
proﬁle compared with nonsmokers. For many years, several
STEMI studies have investigated the impact of CS on
mortality, and have demonstrated conﬂicting results (3–5).
Consequently, there are several issues of the smoker’s
paradox that should be highlighted.See page 372First, even though smokers have had superior survival to
that of nonsmokers in the ﬁbrinolytic era (2), this ﬁnding
has not been consistently reproduced in more contemporary
(invasive) STEMI reports (4,5). In addition to promoting
atherosclerosis, studies have demonstrated that exposure to
CS is known to impair vascular endothelial function,
enhance platelet aggregation, and decrease ﬁbrinolytic
factors, raising the risk of arterial thrombosis (6). Therefore,
acute coronary artery obstructions in individuals who smoke
are likely more thrombogenic and less atherogenic than
those of nonsmokers. In such a highly thrombotic setting,
ﬁbrinolytic therapy may perform particularly well, superior
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Lilly and Company.nonsmokers. A hypothesis of highly-thrombotic lesions in
smokers is also suggested by an enhanced risk of stent
thrombosis following primary angioplasty (7). Second,
epidemiological studies have shown that CS increases the
risk of sudden cardiac death. Furthermore, in the setting of
an acute coronary syndrome, a higher case fatality before
admission to the hospital has been postulated in smokers
compared with nonsmokers. Therefore, surviving smokers
presenting with STEMI might represent a highly-selected
and less-risky population. Third, even after adjusting for
baseline characteristics, we cannot exclude that the remain-
ing protective effect observed in previous studies was due to
residual unmeasured confounders. Fourth, little is known
about the long-term outcome of smokers presenting with an
acute coronary syndrome.
In this issue of JACC: Cardiovascular Interventions, Rob-
ertson et al. (8) publish a substudy of the ACUITY (Acute
Catheterization and Urgent Intervention Triage Strategy)
trial that examined whether smoking status had an impact in
the long-term clinical outcome in patients with non-
STEMI. For this purpose, the 13,189 patients enrolled in
the trial were grouped according to their baseline CS status
(8). As expected and as previously reported in other studies,
current smokers were younger, more frequently male, and
had a lower prevalence of comorbidities compared with
nonsmokers. By univariate analysis, smokers had lower
1-year mortality but had an increased mortality risk after
controlling for baseline characteristics (8). Similar to the
traditional smoker’s paradox, this opposite version of the
paradox may also be tainted by unknown confounders.
For example, because of the sample size, the investigators
selected a limited number of baseline variables for the
multivariate Cox regression analysis. Notably, individuals
who smoked had a worse left ventricular ejection fraction
than did nonsmokers; however, the investigators did not
control for this parameter (8). Studies have demonstrated
that patients presenting with an acute coronary syndrome
and left ventricular systolic dysfunction have increased mor-
tality at 6 months and 1 year (9–11). It remains entirely
plausible that smokers fared worst in the study by Robertson
et al. (8) as a consequence of a greater myocardial impairment.
Persistent smokers in the presence of established coro-
nary artery disease have an increased risk of reinfarction and
death, including sudden cardiac death. Furthermore, a
30-year follow-up study in patients undergoing coronary
stenting demonstrated that failure to quit smoking resulted
in 2.1 life-years lost (12). In the Robertson et al. study (8),
smoking cessation rates after hospital discharge were not
reported, and although speculative, the worse outcome
observed in the group of smokers could be attributable to
clustering of adverse events in the subset of persistent
smokers.
Despite the large number of available behavioral and
pharmacological interventions for tobacco use and the rapid
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381reduction of cardiac risk achieved after quitting, smoking
cessation success rates are staggeringly low. At the same
time, hospitalization provides an excellent opportunity to
start tobacco use interventions because of its smoke-free
environment. Also, hospitalized patients can perceive their
vulnerability to tobacco, which may reinforce the need for
quitting. Regrettably, such an in-hospital opportunity is
seldom recognized. Studies demonstrate that many hospitals
do not consistently offer tobacco use interventions to their
patients. This vexing problem is currently being addressed
by the Joint Commission for Smoking Cessation (13). This
commission launched its new “Tobacco Cessation Perfor-
mance Measure Set” on January 1, 2012 (13). Hopefully,
nationwide quality-control measures will help us see this
pivotal in-hospital opportunity to provide tobacco use
interventions.
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